文献速递肝肾功能剂量调整药物相互作用治疗药物监测与药物基因组学

二甲双胍与西咪替丁的全身生理药代动力学药物-药物-基因相互作用模型

A Comprehensive Whole-Body Physiologically Based Pharmacokinetic Drug-Drug-Gene Interaction Model of Metformin and Cimetidine in Healthy Adults and Renally Impaired Individuals.
PubMed 文献 · Clin Pharmacokinet · 2020-01-01

模型所有模拟的AUC和Cmax比值均在观察值1.5倍以内,并揭示严重肾病中存在反向调节机制。作者建议重新审视现行二甲双胍肾功能不全用药指南。

要点

  • 模型可预测二甲双胍在药物-基因、药物-药物相互作用及不同肾功能阶段下的药代动力学。
  • 所有模拟的药物相互作用AUC和Cmax比值均在观察值1.5倍以内。
  • 严重肾病患者二甲双胍暴露存在反向调节机制,模型已基于临床前数据纳入。

核心结论

  • 全身PBPK模型可用于预测二甲双胍在药物-基因相互作用、药物-药物相互作用及不同肾病阶段下的药代动力学。
  • 现行二甲双胍肾功能不全治疗指南应重新审查,以避免CKD3患者过量用药并允许CKD4患者接受二甲双胍治疗。

研究设计与样本

  • 在PK-Sim®(版本8.0)中开发二甲双胍和西咪替丁的全身生理药代动力学模型。

主要发现

  • 建立的PBPK模型充分描述了现有临床数据,包括所研究的药物-基因相互作用、药物-药物相互作用和药物-药物-基因相互作用研究以及肾功能不全时的二甲双胍暴露。
  • 所有模拟的药物相互作用AUC和Cmax比值均在观察值1.5倍以内。
  • 肾功能不全患者的临床数据显示二甲双胍暴露随肾功能下降而预期增加,但也表明严重肾病中存在反向调节机制;这些机制基于临床前物种发现被纳入模型。

临床怎么用

  • 模型文件将在Open Systems Pharmacology模型库中免费提供。
  • 临床可参考模型预测结果评估二甲双胍在药物相互作用和肾功能不全患者中的暴露变化。
  • 建议重新审视现行指南对CKD3和CKD4患者二甲双胍用药的限制。

局限性

  • 反向调节机制基于临床前物种发现并纳入模型,尚未在人体中直接验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Metformin is a widely prescribed antidiabetic BCS Class III drug (low permeability) that depends on active transport for its absorption and disposition. It is recommended by the US Food and Drug Administration as a clinical substrate of organic cation transporter 2/multidrug and toxin extrusion protein for drug-drug interaction studies. Cimetidine is a potent organic cation transporter 2/multidrug and toxin extrusion protein inhibitor. OBJECTIVE: The objective of this study was to provide mechanistic whole-body physiologically based pharmacokinetic models of metformin and cimetidine, built and evaluated to describe the metformin-SLC22A2 808G>T drug-gene interaction, the cimetidine-metformin drug-drug interaction, and the impact of renal impairment on metformin exposure. METHODS: Physiologically based pharmacokinetic models were developed in PK-Sim® (version 8.0). Thirty-nine clinical studies (dosing range 0.001-2550 mg), providing metformin plasma and urine data, positron emission tomography measurements of tissue concentrations, studies in organic cation transporter 2 polymorphic volunteers, drug-drug interaction studies with cimetidine, and data from patients in different stages of chronic kidney disease, were used to develop the metformin model. Twenty-seven clinical studies (dosing range 100-800 mg), reporting cimetidine plasma and urine concentrations, were used for the cimetidine model development. RESULTS: The established physiologically based pharmacokinetic models adequately describe the available clinical data, including the investigated drug-gene interaction, drug-drug interaction, and drug-drug-gene interaction studies, as well as the metformin exposure during renal impairment. All modeled drug-drug interaction area under the curve and maximum concentration ratios are within 1.5-fold of the observed ratios. The clinical data of renally impaired patients shows the expected increase in metformin exposure with declining kidney function, but also indicates counter-regulatory mechanisms in severe renal disease; these mechanisms were implemented into the model based on findings in preclinical species. CONCLUSIONS: Whole-body physiologically based pharmacokinetic models of metformin and cimetidine were built and qualified for the prediction of metformin pharmacokinetics during drug-gene interaction, drug-drug interaction, and different stages of renal disease. The model files will be freely available in the Open Systems Pharmacology model repository. Current guidelines for metformin treatment of renally impaired patients should be reviewed to avoid overdosing in CKD3 and to allow metformin therapy of CKD4 patients.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Hanke N, Türk D, Selzer D, et al. A Comprehensive Whole-Body Physiologically Based Pharmacokinetic Drug-Drug-Gene Interaction Model of Metformin and Cimetidine in Healthy Adults and Renally Impaired Individuals. Clin Pharmacokinet. 2020. PMID: 32449077. doi:10.1007/s40262-020-00896-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。